Skip to main content
Midas Edge

Korsana Biosciences, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

KRSA$31.17+0.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

ExhibitNumberDescriptionFormFileNo.FilingDateExhibitNumber
2.1Agreement and Plan of Merger and Reorganization, dated as of April 1, 2026, by and among Cyclerion Therapeutics, Inc., Cariboos Merger Sub Corp., Cariboos Merger Sub II, LLC and Korsana Biosciences, Inc.8-K001-38787April 1, 20262.1
2.2Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of April 17, 2026, by and among Cyclerion Therapeutics, Inc., Cariboos Merger Sub Corp., Cariboos Merger Sub II, LLC and Korsana Biosciences, Inc.8-K001-38787September 11, 20262.2
3.1Restated Articles of Organization of Cyclerion Therapeutics, Inc.S-8333-230615March 19, 20194.1
3.2Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc., dated May 15, 2023.8-K001-38787May 15, 20233.1
3.3Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc., dated May 19, 2023, designating the Series A Convertible Preferred Stock.8-K001-38787May 25, 20233.1
3.4Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc., effective September 8, 2026 (Reverse Stock Split).8-K001-38787September 11, 20263.4
3.5Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc., effective September 8, 2026 (Name Change).8-K001-38787September 11, 20263.5
3.6Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc. designating the Series B Non-Voting Convertible Preferred Stock, effective September 8, 2026.8-K001-38787September 11, 20263.6
3.7Amended and Restated Bylaws of Cyclerion Therapeutics, Inc.S-8333-230615March 19, 20194.2
4.1Form of Merger Pre-Funded Warrant.8-K001-38787September 11, 20264.2
10.1†Contingent Value Rights Agreement, dated as of September 8, 2026, by and between Cyclerion Therapeutics, Inc. and Broadridge Corporate Issuer Solutions, LLC, as rights agent.8-K001-38787September 11, 202610.5
10.2Form of Indemnification Agreement for directors and officers of the Company.8-K001-38787September 11, 202610.6
10.3#Korsana Biosciences, Inc. 2025 Equity Incentive Plan.S-4333-295175April 20, 202610.19
10.4#First Amendment to Korsana Biosciences, Inc. 2025 Equity Incentive Plan.S-4/A333-295175July 10, 202610.20
10.5#Korsana Biosciences, Inc. 2026 Stock Incentive Plan.8-K001-38787September 11, 202610.9
10.6#Korsana Biosciences, Inc. 2026 Employee Stock Purchase Plan.8-K001-38787September 11, 202610.10
10.7#Amended and Restated Offer Letter, dated as of September 8, 2026, by and between Korsana Biosciences, Inc. and Jonathan Violin, Ph.D.8-K001-38787September 11, 202610.19
10.8#Amended and Restated Offer Letter, dated as of September 8, 2026, by and between Korsana Biosciences, Inc. and Mark Vignola, Ph.D.8-K001-38787September 11, 202610.20
10.9#Amended and Restated Offer Letter, dated as of September 8, 2026, by and between Korsana Biosciences, Inc. and Matthew Leoni, M.D.8-K001-38787September 11, 202610.21
ExhibitNumberDescription
31.1*Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**††Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**††Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
  • Filed herewith.

** Furnished herewith.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.